The global albumin (as excipient) market was valued at US$ 0.81 billion in 2021. The market is projected to expand at a CAGR of 6.3% from 2022 to 2031, reaching more than US$ 1.7 billion by the end of 2031. Increasing use of albumin as a stabilizing agent, carrier protein, and formulation component in biologics and pharmaceutical products is driving market growth worldwide. Albumin-based excipients play an important role in improving drug stability, extending shelf life, and enhancing the delivery performance of various therapeutic formulations.
Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3984
The growing development of biologics, vaccines, and advanced therapies is significantly boosting demand for albumin as an excipient. Pharmaceutical and biotechnology companies are increasingly utilizing albumin-based solutions in injectable formulations, protein therapeutics, and cell-based therapies due to their biocompatibility and functional properties. Additionally, rising investments in biopharmaceutical research and increasing demand for innovative drug delivery technologies are expected to support market expansion throughout the forecast period.
Technological advancements in recombinant albumin production, purification processes, and formulation technologies are transforming the albumin (as excipient) market landscape. Manufacturers are focusing on improving product quality, safety, and scalability to meet increasing demand from pharmaceutical and biotechnology sectors. Furthermore, growing research activities in personalized medicine, gene therapies, and biologics development are expected to create new growth opportunities during the forecast period.
Key Findings of the Market Report
- Increasing adoption of biologics and advanced therapies is expected to drive market growth.
● Albumin is widely used as a stabilizer and carrier in pharmaceutical formulations.
● Rising demand for injectable drugs is supporting market expansion.
● Recombinant albumin technologies are gaining importance in biopharmaceutical production.
● Growing investments in drug development are creating new market opportunities.
Global Albumin (as Excipient) Market: Growth Drivers
- Increasing demand for biologic drugs and protein-based therapies is significantly boosting market growth.
- Rising use of albumin as a stabilizing agent in pharmaceutical formulations is supporting product adoption.
- Growing investments in vaccine development, cell therapies, and advanced drug delivery systems are accelerating market expansion.
- Technological advancements in recombinant albumin production are improving supply reliability and product performance.
- Increasing focus on innovative therapeutics and personalized medicine is expected to support long-term market growth.
Global Albumin (as Excipient) Market: Regional Landscape
- North America is expected to hold a significant market share owing to advanced biopharmaceutical research, strong healthcare infrastructure, and presence of leading biotechnology companies.
- Europe is anticipated to witness steady growth driven by increasing biologics production, pharmaceutical innovation, and regulatory support for advanced therapies.
- Asia Pacific is projected to experience rapid growth due to expanding biotechnology industries, increasing healthcare investments, and rising demand for pharmaceutical products.
Global Albumin (as Excipient) Market: Key Players
Leading companies are focusing on advanced production technologies, quality improvements, strategic collaborations, and expansion of biopharmaceutical solutions to strengthen their market position.
- CSL Limited
● Grifols S.A.
● Takeda Pharmaceutical Company Limited
● Bio-Rad Laboratories, Inc.
● Thermo Fisher Scientific Inc.
● Merck KGaA
● FUJIFILM Irvine Scientific
● Albumedix Ltd.
Key Developments
- Companies are investing in recombinant albumin technologies, advanced purification methods, and biopharmaceutical formulation solutions to enhance product safety and performance.
- Increasing adoption of biologics, vaccines, and next-generation therapies is accelerating innovation across the albumin (as excipient) industry.
Global Albumin (as Excipient) Market: Segmentation
By Source Type
- Human Serum Albumin
● Recombinant Albumin
● Animal-derived Albumin
By Application
- Drug Formulation
● Vaccine Stabilization
● Cell Culture Media
● Protein Therapeutics
● Gene & Cell Therapy
By End-user
- Pharmaceutical Companies
● Biotechnology Companies
● Research Institutes
● Contract Manufacturing Organizations (CMOs)
By Region
- North America
● Europe
● Asia Pacific
● Latin America
● Middle East & Africa
Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=3984<ype=S
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com